Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference

proton density fat fraction (MRI-PDFF) which has shown at least equivalence in accuracy for quantifying hepatic steatosis with both 1H Magnetic Resonance Spectroscopy and with histological grade, across

vibration controlled transient elastography
diabetes
fatty liver
shear wave elastography
steatosis
  • 0 views
  • 03 Jun, 2020
  • 6 locations
The Sonic Incytes Liver Incytes System Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF

The main purpose of this study is to compare the effectiveness of various non-invasive elastography techniques at determining liver stiffness measures in human subjects. Specifically, the investigators are comparing MRE and FibroScan to Vibroelastography (VE, Liver Incytes System). These techniques are used to measure stiffness in the liver.

  • 0 views
  • 02 Jan, 2021
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

specific ultrasound-derived biomarkers with the liver fat percentage obtained from MRI Proton Density Fat Fraction (MRI-PDFF) measurements. All subjects enrolled in this study will undergo two

  • 0 views
  • 15 Dec, 2020
  • 2 locations
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD

with non-alcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction (MRI-PDFF) and MR spectroscopy as the reference standard.

fatty liver
alcoholic fatty liver
MRI
magnetic resonance spectroscopy
liver disease
  • 0 views
  • 24 Jan, 2021
Comparison of The Effects of Thiazolidinediones(TZD) Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

MRI-PDFF in co-localized regions of interest within nine liver segments between three groups.

diabetes
fatty liver
pioglitazone
type 2 diabetes mellitus
liver disease
  • 0 views
  • 26 Oct, 2020
  • 1 location
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment

  • 0 views
  • 17 Dec, 2020
  • 1 location
A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

The main objective of this study is to evaluate safety and efficacy of ALS-L1023 in patients with Non-alcoholic steatohepatitis

fatty liver
mri-pdff
  • 9 views
  • 18 Jan, 2021
  • 1 location
Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)

This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.

  • 209 views
  • 14 Jan, 2021
  • 24 locations
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD) a Metabolic Syndrome With Insulin Resistance Increased Hepatic Lipids and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

The purpose of this study is to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.

diabetes
semaglutide
fatty liver
insulin
insulin resistance
  • 0 views
  • 22 Oct, 2020
  • 3 locations
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks. Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.

fatty liver
cirrhosis
  • 69 views
  • 23 Sep, 2020
  • 1 location